Percutaneous transluminal angioplasty of complex aortoiliac occlusive disease secondary to Takayasu's aortoarteritis in a young female.

As the initial treatment of patients with the iliac occlusive disease, percutaneous transluminal angioplasty (PTA) became common. Though not supported by the latest TransAtlantic Inter-Society Consensus (TASC) II guidelines, percutaneous treatment of complex aortoiliac lesions is possible and provides comparable angiographic and clinical outcomes compared to open surgery at both short- and long-term follow-up, also in complex lesion settings. TASC C and D lesions with the latest instruments, procedures, and modalities may also be managed endovascularly. It provides new opportunities for a population of highly comorbid patients. We assume that the outcomes of endovascular therapy for aortoiliac lesions in the setting of Takayasu's arteritis will be further enhanced through continuous technological progress and new advances in materials. In light of the current progression towards minimally invasive procedures, a growing number of skilled centres should be able to treat by endovascular intervention the great majority of all arterial pathologies.

Increased renal corticomedullary FDG activity in a patient of NHL-malignant or benign?

Authors describe diagnostic dilemma of differentiating pyelonephritis with lymphomatous involvement of kidney in a known case of lymphoma. FDG uptake pattern was non-discriminatory and pyelonephritis diagnosed retrospectively on follow up study. Authors emphasize the importance of recognition of features and subtle clues of infection evident on CT component of PET-CT.

Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy.

OBJECTIVE: To record the effect of pyrazinamide on uric acid in patients of tuberculosis. DESIGN: Descriptive and observational study. PLACE AND DURATION OF STUDY: Chandka Medical College Hospital, Larkana from February 2000 to January 2003. PATIENTS AND METHODS: All patients receiving anti-tuberculosis drugs with pyrazinamide were included. Serum uric acid levels were monitored at weeks 0, 2, 8 and 12 of therapy. Serum creatinine was done at weeks 0, 8 and 12. RESULTS: Results were reported on 216 patients. Mean uric acid and creatinine levels at the start of therapy, i.e., week '0' were 5.07 -/+ 0.57 mg/dl and 0.87 -/+ 0.11 mg/dl respectively. The results show significant increase in uric acid levels from week '0' to week '2', at the end of week '8', the levels remained elevated and there was no statistical significant difference from that at week '2'. The uric acid levels reduced at week '12' after pyrazinamide was stopped and the difference was significant. Despite that renal function steadily improved with the treatment of tuberculosis to the extent that comparable pre-treatment values were obtained at the end of treatment. CONCLUSION: Anti-tuberculous therapy with pyrazinamide affects the uric acid levels early. This change is reversible after the withdrawal of the agent.